Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer.
INTRODUCTION
Bisphosphonates are widely used for the prevention and treatment of osteoporosis; in 2007, nearly 6 million patients received prescriptions for this indication. 1 Aminobisphosphonates, the most active of these drugs, also have cytostatic, proapoptotic, and antimetastatic properties 2 and have been inversely associated with breast cancer risk in some, [3] [4] [5] [6] but not all, 7 studies. Hormonally mediated endometrial cancer shares many risk factors with breast cancer, 8 and previous studies have reported reduced risk of endometrial cancer in women with a history of fractures, 9,10 providing support for this thesis. A few small retrospective studies of bisphosphonate use and endometrial cancer have been published with inconsistent findings. [11] [12] [13] We examined this association in the well-annotated Women's Health Initiative (WHI), a prospective cohort involving four randomized clinical trials (WHI-CT) and a large observational study (WHI-OS). Use of oral bisphosphonates was ascertained for WHI participants at baseline and over the follow-up period.
METHODS

Study Population
WHI enrolled 161,808 postmenopausal women, age 50 to 79 years, from 40 clinical sites across the United States between 1993 and 1998. WHI-OS participants were generally similar to those of WHI-CT but were ineligible or unwilling to be included in a randomized trial. Details of the WHI recruitment, eligibility criteria, and protocols have been published elsewhere.
14-17 All participants provided informed consent. The institutional review boards at all WHI institutions approved the protocols and procedures.
Measurement of Health Characteristics and Oral Bisphosphonate Use
All women were personally interviewed regarding general health information at baseline. An inventory of all
current, regularly used medications, including oral bisphosphonates, was taken at baseline and at 1, 3, and 6 years after random assignment for WHI-CT components. The same inventory was performed at baseline and 3 years after for WHI-OS. Participants were instructed to provide medication bottles or packaging for drugs taken at least twice per week during the previous 2 weeks. All medications were matched to the Medi-Span (Indianapolis, IN) Master Drug Data Base to ascertain detailed ingredient information. Intravenous bisphosphonates were not included.
Follow-Up for Endometrial Cancer Diagnoses
WHI participants reported diagnoses of invasive endometrial cancer, or hysterectomy for any reason, semi-annually (WHI-CT) or annually (WHI-OS). Incident endometrial cancers were adjudicated centrally by physicians through medical and pathology records review.
15 Follow-up was censored at the earliest of the following events: time of hysterectomy, last known followup, or August 2010. The vast majority of endometrial cancers (81%) were diagnosed at local stage.
Study Exclusions
Women reporting a history of endometrial or breast cancer, hysterectomy, antiestrogen use, or hormone therapy specifically to treat bone fracture before study entry were excluded from analyses, as were women with missing information on endometrial cancer or hysterectomy at baseline or during follow-up. Requiring women to have an intact uterus at baseline led to the exclusion of all 10,739 women who participated in an estrogen-alone randomized trial. The final analytic study population included 89,918 WHI participants.
Statistical Analyses
We estimated adjusted hazard ratios (HRs) with 95% CIs from Cox regression models comparing bisphosphonate users to nonusers, treating bisphosphonate use as a time-varying never/ever variable, with baseline hazard stratified by WHI study component and adjustment for the following baseline covariates: age, 5-year hip fracture probability, 18 body mass index (BMI), race, education, smoking status, estrogen-only use, estrogenprogestin use, oral contraceptive use, parity, and mammography. The 5-year hip fracture probability considers age, race, weight, height, selfreported health, diabetes, physical activity, bone fracture after age 54 years, parental hip fracture, smoking, and corticosteroid use. We considered further stratification by intervention arm of WHI-CT in sensitivity analyses. The proportional hazards assumption was assessed by testing for interactions with log-transformed time on study.
Bisphosphonate use was treated as a time-varying never/ever variable by updating baseline use at years 1, 3, and 6 for women in WHI-CT and at year 3 for women in WHI-OS. We permitted nonusers to become users over followup, but users could not become nonusers. We assessed interactions in the association between bisphosphonate use and endometrial cancer by age, BMI, and hip fracture probability score, each measured at baseline. All statistical tests were performed using SAS version 9.2 (SAS Institute, Cary, NC) and were two-sided, with P Յ .05 considered statistically significant.
RESULTS
Of the 89,918 women included in our analyses, 39,261 (44%) were enrolled onto one or more of the three randomized trials, and 50,657 (56%) were exclusively in the WHI-OS. Bisphosphonate use at baseline was uncommon (2%) but had markedly increased by year 6 (10%). Alendronate was the most common type of bisphosphonate, accounting for more than 90% of use.
Users of any type of bisphosphonate at baseline were slightly older, more highly educated, less likely to be current smokers, and leaner than nonusers (Table 1) . Users and nonusers were not that different in their use of hormone therapy before enrollment. Compared with nonusers, however, a lower percentage of bisphosphonate users at baseline participated in the combined estrogen plus progestin randomized trial (19% of nonusers and 11% of users, but treatment and placebo arms were well-balanced between users and nonusers).
During study follow-up, 1,123 women were diagnosed with incident endometrial cancer (1,070 nonusers and 53 users of bisphosphonates). The crude incidence of endometrial cancer was 12 per 10,000 person-years of follow-up among nonusers and eight per 10,000 person-years among users of any type of bisphosphonate (seven per 10,000 person-years among alendronate users). Bisphosphonate use was inversely associated with age-adjusted endometrial cancer risk (HR, 0.76; 95% CI, 0.61 to 0.94; P ϭ .01; Table 2 ). The inclusion of confounders, selected a priori, left the association largely unchanged (bisphosphonate users: HR, 0.80; 95% CI, 0.64 to 1.00; P ϭ .05; alendronate users: HR, 0.77; 95% CI, 0.61 to 0.98; P ϭ .03). In models without adjustment for variables already accounted for in the Robbin's fracture probability (age, race, smoking, and BMI), the HR for bisphosphonate use changed from 0.80 (95% CI, 0.64 to 1.00) to 0.74 (95% CI, 0.59 to 0.92).
The magnitude of HRs was similar for different durations of use, but the HRs were less precise than the estimate ignoring duration of use. Results were largely unchanged in models that also stratified the baseline hazard by intervention arm of each randomized trial. We found no statistically significant interactions with BMI (P ϭ .41), age at baseline (P ϭ .21), or hip fracture probability score (P ϭ .83).
DISCUSSION
In this large cohort of postmenopausal women, oral bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk. The mechanisms underlying the observed relationship are unclear. Bisphosphonates prevent metastasis to bone, 19 and numerous in vivo studies have demonstrated their proapoptotic and antiangiogenic properties. 20, 21 This association might be hormonally mediated, especially given that bisphosphonate history is most strongly, if not exclusively, associated with lower risk of hormone receptor-positive breast cancer as shown in the study of contralateral breast cancer by Monsees et al. 6 To our knowledge, this is the first prospective study to evaluate bisphosphonate use and endometrial cancer risk. The relationship has been evaluated in the United Kingdom General Practice Database, where the findings were inconsistent, 11, 12 and the Cancer in the Ovary and Uterus Study (CITOUS), which found that the use of bisphosphonates was associated with reduced risk of endometrial cancer. 13 The 20% reduction in risk we observed is far more modest than the 60% reduction reported in CITOUS. Although CITOUS determined bisphosphonate use from pharmacy records, limiting the potential for recall bias, this bias could have been introduced from the measurement of other covariates, which were collected retrospectively from self-report.
The results presented here have limitations. This analytic study design is observational rather than randomized.
22 Therefore, confounding is a possibility because women using oral bisphosphonates may have done so because of their high fracture risk as a result of low endogenous estrogen, perhaps as a consequence of low weight, which could place them at low endometrial cancer risk. 23 We carefully controlled for weight and considered various approaches to define this risk factor; all seemed to provide similar control for any residual confounding with little change in our measures of association. We also took fracture risk, as summarized by the index of Robbins et al, 18 into account. This fracture probability has proved to be a valid measure of fracture risk, although it does not include measured bone mineral density. Thus, our full-adjustment approach to protect against residual confounding leads us to be conservative about the strength of the association. Finally, although this is a large study, our numbers were Abbreviations: CT, clinical trial; E, estrogen; EϩP, estrogen plus progestin; SD, standard deviation.
‫ء‬
Among those remaining at risk of endometrial cancer at year 3. †Calculated as described in Robbins et al. 18 ‡Percentages do not sum to 100% as a result of overlap of study components. 
Users reported at least 2 weeks of use; nonusers include never-users and those who used for Ͻ 2 weeks. Baseline oral bisphosphonate use was updated at years 1, 3, and 6 for women in WHI-CT and at year 3 for women in WHI-OS.
†Median follow-up time of 12.5 years. ‡Baseline hazard stratified by Women's Health Initiative study component. §Adjusted for age, 5-year hip fracture probability, body mass index, race, education, smoking status, estrogen-only use, estrogen-progestin use, oral contraceptive use, parity, and mammography, all measured at baseline. Other includes etidronate disodium and tiludronate disodium.
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www.jco.org limited to explore heterogeneity in associations according to endometrial cancer subtypes. Given that type II endometrial tumors are less likely to be hormonally mediated than type I tumors, 24 it is plausible that bisphosphonate use would be most relevant to risk of type I tumors; however, the modest number of type II tumors in the study population (approximately 10%) precluded separate evaluation by tumor type.
The prevalence of bisphosphonate use was initially low in this cohort. However, we were able to incorporate the substantial increase in use with a time-varying variable. All study participants were instructed to present regularly used medications during the scheduled drug inventories. Any misclassification or under-reporting of exposure history is unlikely to differ between women who developed endometrial cancer during follow-up and those who did not; nondifferential misclassification would have yielded attenuated measures of the true association. 25 The strengths of our large study include the prospective collection of detailed data on endometrial cancer risk factors, accounting for prior and incident hysterectomy, and centralized adjudication of endometrial cancer diagnoses. In summary, our findings suggest that use of bisphosphonates is modestly associated with reduced endometrial cancer risk, a finding consistent with the inverse association between use of this medication and breast cancer risk.
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